Expert Consensus on the Core Competency Framework of Chinese Clinical Pharmacist (2023)

In the new era of hospital pharmaceutical service transformation, higher standards and requirements are constantly put forward for clinical pharmacists to participate in patient-centered pharmaceutical professional technical services. The formulation of competency standards has become an international trend. However, research on pharmacist competency is still limited in China, and there is a lack of core competency framework for clinical pharmacists. In order to facilitate the construction of pharmacist competency, Peking Union Medical College Hospital, China Medical Board and Chinese Hospital Association Pharmaceutical Specialized Committee organized multidisciplinary experts in pharmacy, clinical medicine, education and administration to formulate Expert Consensus on the Core Competency Framework of Chinese Clinical Pharmacist (2023), which is based on domestic and foreign research results and clinical pharmacy practice in China. This specialist consensus, adopting the modified Delphi method to formulate the core competency framework of Chinese clinical pharmacist, determines six first-level item of core competencies that clinical pharmacists should have, including professionalism, knowledge and skill, patient care, communication and collaboration, teaching and lifelong learning. The six first-level items have twenty-two second-level items, which are explained in detail. This consensus can provide an important basis and exploration direction for the training and ability enhancement of clinical pharmacists in China

Guideline for stratified screening and surveillance in patients with high risk of primary liver cancer (2020)

The age-adjusted incidence of primary liver cancer (PLC) has been declining in China. However, PLC cases in China account for 55% globally. The disease burden is still high and the five-year survival rate has not improved significantly in the past two decades. This guideline outlines PLC screening in populations with high risk, both in the hospital and community settings. Liver cirrhosis and chronic hepatitis B are the main causes of PLC in China. For better PLC surveillance and screening in clinical practices, it is recommended that these populations be stratified into four risk levels, namely, low-, intermediate-, high-, and extremely high-risk. A lifelong surveillance is suggested for those with risks of PLC. The intervals and tools for surveillance and screening are recommended based on risk levels. Abdominal ultrasonography combined with serum alpha-fetoprotein tests (routine surveillance) is recommended every 6 months for high risk PLC. Routine surveillance every 3 months and enhanced CT/MRI examinations every 6-12 months is recommended for those with extremely high risk of PLC. The surveillance interval can be extended to one year or longer for those with low or intermediate risk because the annual incidence of low risk PLC is relatively low. The cost-effectiveness of these recommendations remains to be evaluated